That's pretty easy.
Company were forecasting BLA in H1 2023.
That is based on the 6 month approval timeline post submission ( Provided by priority review status )
So they submit by Dec 31st, and they will get a PDUFA date before June 30th, ie commercialization H1 2023.
That is based on the last company announcement in November - after they released the long term survival data.
Or in other words.... prior to 12 days time.
I think share holders will not be updated until FDA have confirmed / accepted the resubmission.
GVHD the first step, page-65
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.045(4.07%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.16 | $1.08 | $4.681M | 4.170M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 99680 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 31000 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |